Literature DB >> 16822826

Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia.

C Moran1, R Azziz, N Weintrob, S F Witchel, V Rohmer, D Dewailly, J A M Marcondes, M Pugeat, P W Speiser, D Pignatelli, B B Mendonca, T A S Bachega, H F Escobar-Morreale, E Carmina, F Fruzzetti, F Kelestimur.   

Abstract

CONTEXT: Because many women with 21-hydroxylase (21-OH)-deficient nonclassic adrenal hyperplasia (NCAH) carry at least one allele affected by a severe mutation of CYP21, they are at risk for giving birth to infants with classic adrenal hyperplasia (CAH).
OBJECTIVE: Our objective was to determine the frequency of CAH and NCAH infants born to mothers with 21-OH-deficient NCAH. DESIGN AND
SETTING: We conducted an international multicenter retrospective/prospective study. PATIENTS AND METHODS: The outcome of 203 pregnancies among 101 women with 21-OH-deficient NCAH was reviewed. The diagnosis of 21-OH-deficient NCAH was established by a basal or post-ACTH-stimulation 17-hydroxyprogesterone level of more than 10 ng/ml (30.3 nmol/liter). When possible, genotype analyses were performed to confirm CAH or NCAH in the offspring.
RESULTS: Of the 203 pregnancies, 138 (68%) occurred before the mother's diagnosis of NCAH and 65 (32%) after the diagnosis. Spontaneous miscarriages occurred in 35 of 138 pregnancies (25.4%) before the maternal diagnosis of NCAH, and in only four of 65 pregnancies (6.2%) after the diagnosis (P < 0.002). Four (2.5%; 95% confidence interval, 0.7-6.2%) of the 162 live births were diagnosed with CAH. To date, 24 (14.8%; 95% confidence interval, 9.0-20.6%) children, 13 girls and 11 boys, have been diagnosed with NCAH. The distribution of NCAH children and their mothers varied significantly by ethnicity (P < 0.0001, for both).
CONCLUSIONS: The risk of a mother with 21-OH-deficient NCAH for giving birth to a child affected with CAH is 2.5%; at least 14.8% of children born to these mothers have NCAH.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822826     DOI: 10.1210/jc.2006-0062

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  36 in total

Review 1.  The next 150 years of congenital adrenal hyperplasia.

Authors:  Adina F Turcu; Richard J Auchus
Journal:  J Steroid Biochem Mol Biol       Date:  2015-06-03       Impact factor: 4.292

Review 2.  The way toward adulthood for females with nonclassic congenital adrenal hyperplasia.

Authors:  Georgia Ntali; Sokratis Charisis; Christo F Kylafi; Evangelia Vogiatzi; Lina Michala
Journal:  Endocrine       Date:  2021-04-14       Impact factor: 3.633

Review 3.  Disorders of Sexual Development in Adult Women.

Authors:  Veronica Gomez-Lobo; Anne-Marie Amies Oelschlager
Journal:  Obstet Gynecol       Date:  2016-11       Impact factor: 7.661

4.  Phenotypic profiling of parents with cryptic nonclassic congenital adrenal hyperplasia: findings in 145 unrelated families.

Authors:  Radha Nandagopal; Ninet Sinaii; Nilo A Avila; Carol Van Ryzin; Wuyan Chen; Gabriela P Finkielstain; Sneha P Mehta; Nazli B McDonnell; Deborah P Merke
Journal:  Eur J Endocrinol       Date:  2011-03-28       Impact factor: 6.664

Review 5.  Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): an update.

Authors:  Christine M Trapp; Sharon E Oberfield
Journal:  Steroids       Date:  2011-12-13       Impact factor: 2.668

6.  Nonclassic congenital adrenal hyperplasia.

Authors:  Selma Feldman Witchel; Ricardo Azziz
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-30

Review 7.  Nonclassic adrenal hyperplasia.

Authors:  Phyllis W Speiser
Journal:  Rev Endocr Metab Disord       Date:  2009-03       Impact factor: 6.514

Review 8.  Biochemical and genetic diagnosis of 21-hydroxylase deficiency.

Authors:  Henrik Falhammar; Anna Wedell; Anna Nordenström
Journal:  Endocrine       Date:  2015-09-04       Impact factor: 3.633

9.  A 31-year-old woman with infertility and polycystic ovaries diagnosed with non-classic congenital adrenal hyperplasia due to a novel CYP21 mutation.

Authors:  H Falhammar; M Thorén; K Hagenfeldt
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

Review 10.  Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Felix G Riepe; Wolfgang G Sippell
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.